Co-opting psychiatry: The alliance between academic psychiatry and the pharmaceutical industry

Epidemiologia e Psichiatria Sociale

Volumn 16, Issue 3, 2007, Pages 192-196

  Moncrieff, Joanna ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL RESEARCH; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DYSLIPIDEMIA; GRAY MATTER; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HEART DISEASE; HUMAN; LONG TERM CARE; MEDICAL EDUCATION; NEUROLOGIC DISEASE; PATIENT CARE; PRACTICE GUIDELINE; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 34447532101     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x00002268     Document Type: Review

References (40)

1. Alex Berenson (2006). Eli Lilly said to play down risk of top pill. New York Times, 17 December 2006.
2. Angst J., Gamma A., Benazzi F., Ajdacic V., Eich & Rossler W. (2003). Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. Journal of Affective Disorders 73, 133-146.
3. BanT. (1996). They used to call it psychiatry. In The Psychopharmacologists, Vol. 1 (ed. D. Healy), pp. 587-620. Altman (Chapman and Hall): London.
4. Breggin P.R. (1993). Toxic Psychiatry. Fontana: London.
5. Collier J. (2007). Inside big pharma's box of tricks. British Medical Journal 334, 209.
6. Craddock N. & Owen M.J. (2005). The beginning of the end for the Kraeplinian dichotomy. British Journal of Psychiatry 186, 364-366.
7. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Mallett R.M., Jones P.B., Leff J. & Murray R.M. (2005). Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 30, 765-774.
8. Dinan T.G. (2004). Schizophrenia and diabetes 2003: An expert consensus meeting. British Journal of Psychiatry, Suppl. Apr., 47, s53-s54.
9. Editor (2005). Corrigendum for Calton, British J Psych 187(2) 195. British Journal of Psychiatry 187, 390.
10. Fisher G., Sheeky K., Launier K. & Lallanilla M. (2004). Drug maker withheld Paxil study data. ABC News, 9 December 2004.
11. Friedman R.A. (2006). Uncovering an epidemic - screening for mental illness in teens. New England Journal of Medicine 355, 2717-2719.
12. Hamilton C. (2003). Growth Fetish. Allen & Unwin: Sydney.
13. Healy D. (2006). Manufacturing consensus. Culture Medicine and Psychiatry 30, 135-156.
14. Heres S., Davis J., Maino K., Jetzinger E., Kissling W. & Leucht S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163, 185-194.
15. Jacyna L.S. (1982). Somatic theories of mind and the interests of medicine in Britain 1850-1879. Medical History 16, 233-258.
16. Kaptchuk T.J. (2001). The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? Journal of Clinical Epidemiology 54, 541-549.
17. Kessler R.C., Coccaro E.F., Fava M., Jaeger S., Jin R. & Walters E. (2006). The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry 63, 669-678.
18. Kirsch I. & Moncrieff J. (2007). Clinical trials and the response rate illusion. Contemporary Clinical Trials 28(4), 348-351.
19. Koran L.M., Chuong H.W., Bullock K.D. & Smith S.C. (2003). Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Journal of Clinical Psychiatry 64, 793-798.
20. Lehtinen V., Aaltonen J., Koffert T., Rakkolainen V. & Syvalahti E. (2000). Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? European Psychiatry 15, 312-320.
21. Lewis B.E. (2003). Prozac and the post-human politics of cyborgs. Journal of Medical Humanities 24, 49-63.
22. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. & HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry 62, 361-370.
23. Melander H., Ahlqvist-Rastad J., Meijer G. & Beermann B. (2003). Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal 326, 1171-1173.
24. Moncrieff J. (1999). An investigation into the precedents of modern drug treatment in psychiatry. History of Psychiatry 10, 475-490.
25. Moncrieff J. (2006). Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Medical Hypotheses 67, 517-523.
26. Moncrieff J. & Cohen D. (2006). Do antidepressants cure or create abnormal brain states? PLoS Medicine 3, e240.
27. Moncrieff J. & Crawford M.J. (2001). British psychiatry in the 20th century - observations from a psychiatric journal. Social Science and Medicine 53, 349-356.
28. Moore S. (2007). First time mental-health screening identifies need. The Press Republican, 28 January 2007.
29. National Institute for Clinical Excellence (2004). Depression: Management of Depression in Primary and Secondary Care. Clinical Practice Guideline Number 23. National Institute for Clinical Excellence: London.
30. Newcomer J.W. & Haupt D.W. (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 51, 480-491.
31. Olfson M., Blanco C., Liu L., Moreno C. & Laje G. (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 63, 679-685.
32. Paykel E.S. & Priest R.G. (1992). Recognition and management of depression in general practice: consensus statement. British Medical Journal 305, 1198-1202.
33. Pharmaceutical Marketing (2000). Practical Guides: Medical Education, Parts I and II. Pharmaceutical Marketing. Retrieved June 4, 2007, from http://www.pmlive.com
34. Rose N. (2004). Becoming neurochemical selves. In Biotechnology, Commerce and Civil Society (ed. N. Stehr), pp. 89-128. Transaction Publishers: New Brunswick (N.J.).
35. Scull A. (1994). Somatic treatments and the historiography of psychiatry. History of Psychiatry 5(17 Pt.1), 1-12.
36. Stagnitti M. (2005). Antidepressant Use in the US Civilian Non-Institutionalised Population, 2002. Statistical Brief #77. Medical Expenditure Panel, Agency for Healthcare Research and Quality: Rockville,MD.
37. Steen R.G., Mull C., McClure R., Hamer R.M. & Lieberman J.A. (2006). Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry 188, 510-518.
38. Swazey J. (1974). Chlorpromazine in Psychiatry. Massachusetts Institute of Technology: Cambridge, MA.
39. Waddington J.L. & Youssef H.A. (1996). Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine 26, 681-688.
40. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A. & Boddington E. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341-1345.